Elanco Animal Health Incorporated (NYSE:ELAN) Stock Has Average Target Price of $29.42

Key Points

• Analysts maintain a moderately bullish view of Elanco Animal Health, with 14 firms assigning a consensus “Moderate Buy” rating and an average 12-month price target of $29.42 versus the stock’s $22.52 opening price.
• Elanco reported quarterly EPS of $0.34, beating the $0.27 consensus estimate, while revenue rose 10.2% year over year to $1.37 billion. The company expects full-year 2026 EPS of $1.10–$1.16.
• Insiders purchased 63,198 shares worth approximately $1.47 million over the past three months, while hedge funds and other institutions own 97.48% of the company.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $29.42.

ELAN has been the topic of a number of research reports. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Jefferies Financial Group cut Elanco Animal Health from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $31.00 to $24.00 in a research note on Tuesday. Morgan Stanley upped their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 22nd. KeyCorp reiterated an "overweight" rating on shares of Elanco Animal Health in a research note on Wednesday, September 30th. Finally, The Goldman Sachs Group began coverage on Elanco Animal Health in a report on Friday, October 16th. They issued a "buy" rating and a $32.00 price target for the company.

Insider Activity at Elanco Animal Health

In other news, Director Michael Harrington bought 5,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares in the company, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shiv O'Neill purchased 3,998 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average cost of $23.58 per share, with a total value of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. This represents a 4.77% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Skylands Capital LLC increased its stake in shares of Elanco Animal Health by 1.1% in the third quarter. Skylands Capital LLC now owns 211,525 shares of the company's stock worth $4,736,000 after buying an additional 2,300 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Elanco Animal Health by 9.6% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 43,133 shares of the company's stock worth $966,000 after purchasing an additional 3,761 shares during the last quarter. Quadrant Capital Group LLC acquired a new stake in shares of Elanco Animal Health in the 3rd quarter valued at about $215,000. Nisa Investment Advisors LLC lifted its position in shares of Elanco Animal Health by 3.4% during the third quarter. Nisa Investment Advisors LLC now owns 19,749 shares of the company's stock worth $442,000 after purchasing an additional 654 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC bought a new position in shares of Elanco Animal Health during the third quarter worth about $601,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $22.52 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health has a 1-year low of $19.40 and a 1-year high of $27.98. The firm has a market capitalization of $11.25 billion, a P/E ratio of -54.94, a P/E/G ratio of 2.01 and a beta of 1.70. The business's 50-day simple moving average is $23.25 and its 200-day simple moving average is $23.57.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the company earned $0.26 EPS. The company's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts predict that Elanco Animal Health will post 1.13 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company's products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.